Effect of Memantine on Prolonging Safe Driving in Early AD: a Pilot Study
Keywords:dementia, driving, Alzheimer’s disease, memantine, feasibility, survival time
To determine the feasibility of conducting an RCT on the potential effectiveness of memantine hydrochloride in prolonging safe driving in mild AD.
A placebo-controlled, double blind randomized trial was conducted. Forty-three individuals ≥60 with mild AD met screening criteria and were randomized. Driving ability was measured by a standardized on-road driving test. Outcomes were driving capacity at 6 and 12 months and completion of the 12-month intervention.
Of 43 participants randomized, 59% of the memantine group and 52% of the placebo group completed the on-road test at 12 months (p = .66). All 13 memantine group participants maintained their driving status at 12 months, whereas only 8 of the 11 placebo group participants did (p = .040, OR = 4.45).
Results provide the framework for designing a rigorous multisite clinical trial of memantine effect on maintaining driving capacity in mild AD.
How to Cite
Copyright (c) 2021 Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors contributing to the Candian Geriatrics Journal retain copyright of their work, with exclusive publication rights granted to the Canadian Geriatrics Society upon article acceptance. Read the journal's full copyright and open access policy.